Keyue Pharmaceutical

Createrna (Keyue Pharmaceutical) is a clinical-stage biopharmaceutical company dedicated to developing transformative complement-targeted therapies for patients with rare and severe immune-mediated diseases. The company's lead asset, KP104, is a first-in-class bifunctional fusion protein that simultaneously targets Complement C5 and Complement Factor D, providing dual inhibition of both the terminal and alternative complement pathways. This innovative approach is designed to offer superior clinical benefits compared to existing single-target inhibitors for conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy. Createrna leverages its deep expertise in complement biology and protein engineering to advance a pipeline of next-generation biologics, including monoclonal antibodies and fusion proteins. Headquartered in Suzhou, China, with a significant research presence in Cambridge, Massachusetts, the company is backed by leading global life science investors and is currently advancing multiple Phase 2 clinical trials globally.